Research programme: viral infection therapeutics - Gemmus Pharma

Drug Profile

Research programme: viral infection therapeutics - Gemmus Pharma

Alternative Names: GP-1001; GP-1681

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gemmus Pharma
  • Class Eicosanoids
  • Mechanism of Action Eicosanoid receptor agonists; G protein-coupled receptor agonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Influenza virus infections; Viral infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for research development in Viral-infections in USA
  • 12 May 2015 GP 1681 is available for licensing as of 12 May 2015. www.gemmuspharma.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top